OtherNeuropharmacology
The dopamine D1 receptor positive allosteric modulator mevidalen (LY3154207) enhances wakefulness in the humanized D1 mouse and in sleep deprived healthy volunteers.
Andrew P McCarthy, Kjell A Svensson, Elaine Shanks, Claire Brittain, Brian J Eastwood, William Kielbasa, Kevin M Biglan and Keith A Wafford
Journal of Pharmacology and Experimental Therapeutics December 10, 2021, JPET-AR-2021-000719; DOI: https://doi.org/10.1124/jpet.121.000719
Andrew P McCarthy
1Neuroscience, Eli Lilly and Company, United States
Kjell A Svensson
1Neuroscience, Eli Lilly and Company, United States
Elaine Shanks
2Exploratory Medicine and Pharmacology, Eli Lilly and Company, United Kingdom
Claire Brittain
3Eli Lilly and Company, United Kingdom
Brian J Eastwood
4Eli Lilly and Company, Canada
William Kielbasa
5Eli Lilly and Company, United States
Kevin M Biglan
5Eli Lilly and Company, United States
Keith A Wafford
3Eli Lilly and Company, United Kingdom
Jump to comment:
No eLetters have been published for this article.
In this issue
OtherNeuropharmacology
D1PAM enhances wakefulness in hD1 mice and humans.
Andrew P McCarthy, Kjell A Svensson, Elaine Shanks, Claire Brittain, Brian J Eastwood, William Kielbasa, Kevin M Biglan and Keith A Wafford
Journal of Pharmacology and Experimental Therapeutics December 10, 2021, JPET-AR-2021-000719; DOI: https://doi.org/10.1124/jpet.121.000719
OtherNeuropharmacology
D1PAM enhances wakefulness in hD1 mice and humans.
Andrew P McCarthy, Kjell A Svensson, Elaine Shanks, Claire Brittain, Brian J Eastwood, William Kielbasa, Kevin M Biglan and Keith A Wafford
Journal of Pharmacology and Experimental Therapeutics December 10, 2021, JPET-AR-2021-000719; DOI: https://doi.org/10.1124/jpet.121.000719
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement